Cargando…

Mucormycosis and glucose‐regulated protein 78 in COVID‐19: Amenable to statin treatment?

Detalles Bibliográficos
Autores principales:	Vuorio, Alpo, Kovanen, Petri T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447360/ https://www.ncbi.nlm.nih.gov/pubmed/34133038 http://dx.doi.org/10.1111/joim.13347

Ejemplares similares

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
por: Vuorio, Alpo, et al.
Publicado: (2021)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten
por: Vuorio, Alpo, et al.
Publicado: (2022)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
por: Vuorio, Alpo, et al.
Publicado: (2022)

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2014)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
por: Kovanen, Petri T., et al.
Publicado: (2023)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Serum glucose-regulated protein 78 (GRP78) levels in COVID-19-associated mucormycosis: results of a case–control study
por: Muthu, Valliappan, et al.
Publicado: (2022)

Should statins be considered for the management of mucormycosis in COVID-19?
por: Chatterjee, Subhankar, et al.
Publicado: (2021)

COVID19 associated mucormycosis: Is GRP78 a possible link?
por: Gumashta, Jyotsna, et al.
Publicado: (2021)

Institutional Amenities
Publicado: (1898)

Institutional Amenities
Publicado: (1898)

GRP78: A possible relationship of COVID-19 and the mucormycosis; in silico perspective
por: Elgohary, Alaa M., et al.
Publicado: (2021)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

COVID-19 and orbital mucormycosis
por: Sarkar, Sandip, et al.
Publicado: (2021)

The Interplay between Glucose-Regulated Protein 78 (GRP78) and Steroids in the Reproductive System
por: Hebert-Schuster, Marylise, et al.
Publicado: (2018)

Black Swan Pandemic and the Risk of Pilot Suicide
por: Vuorio, Alpo, et al.
Publicado: (2020)

Self-Harm in Aviation Medicine—A Complex Challenge During a Pandemic
por: Vuorio, Alpo, et al.
Publicado: (2021)

Safety of Health Care Workers in a War Zone—A European Issue
por: Vuorio, Alpo, et al.
Publicado: (2022)

Mucormycosis in COVID-19: The Indian scenario
por: Ghosh, Ritwik, et al.
Publicado: (2022)

Glucose-regulated protein 78 binds to and regulates the melanocortin-4 receptor
por: Yoon, Ye Ran, et al.
Publicado: (2018)

Amenability
por: Paterson, Alan LT
Publicado: (2014)

Glucose-regulated protein 78 is essential for cardiac myocyte survival
por: Wang, Xiaoding, et al.
Publicado: (2018)

Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases
por: Gonzalez-Gronow, Mario, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_32cbc9dairilb5fobsdr9bejb1